PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v8i4.7607ArticleTargeted Therapy of CEA-CAR-NK Cells Against Colorectal Cancer Cellshttps://artdesignp.com/journal/PAR/8/4/10.26689/par.v8i4.7607ZhengXinyu,ChenXiaomeng,XiaXingzhou,WangWenzhen,LiuQian2024842024-07-17Objective: Investigate the cytotoxic effect of CAR-NK cells targeting CEA on colorectal cancer cells with positive CEA expression. Methods: The mRNA and protein levels of CEA in different CRC cell lines were detected by qRT-PCR and Western blot analysis. Lentiviral transduction was used to construct CAR-NK cells and empty vector CON-NK cells targeting CEA. Fluorescence microscopy and WB were used to determine whether the cells successfully constructed and expressed CAR structures. The effector NK cells were co-cultured with target cells, and the levels of LDH, IFN-γ, and GM-CSF were detected. The killing rate of effector cells was calculated, and the release of cytokines during the killing of target cells by different effector cells was compared. Results: The expression level of CEA in colorectal cancer patients was significantly higher than that in normal samples and other tumor samples, and the prognosis survival time of patients with high CEA expression was lower than that of CRC patients with low or no CEA expression (P < 0.05). The CEA expression of the HT29 cell line was significantly higher than that of the SW1116 cell line at both the mRNA and protein levels. CEA-CAR-NK92 cells and CON-NK92 cells expressed green fluorescence under a microscope, and WB results showed that CEA-CAR-NK92 cells successfully expressed the CAR structure. Compared with CON-NK92 cells and NK92 cells, CEA-CAR-NK92 cells effectively killed HT29 cells (P < 0.05). CEA-CAR-NK92 cells secreted a large amount of IFN-γ and GM-CSF during the killing of HT29 cells, while the cytokine secretion of CON-NK92 cells and NK92 cells was not significant (P < 0.05). Conclusion: CAR-NK92 cells targeting CEA can effectively kill CEA-positive colorectal cancer cells.

Yan H, Talty R, Johnson CH, 2023, Targeting Ferroptosis to Treat Colorectal Cancer. Trends Cell Biol, 33(3): 185–188. https://doi.org/10.1016/j.tcb.2022.11.003

Laskowski TJ, Biederstadt A, Rezvani K, 2022, Natural Killer Cells in Antitumour Adoptive Cell Immunotherapy. Nat Rev Cancer, 22(10): 557–575. https://doi.org/10.1038/s41568-022-00491-0

Klingemann H, 2014, Are Natural Killer Cells Superior CAR Drivers? Oncoimmunology, 3: e28147. https://doi.org/10.4161/onci.28147

Sung H, Ferlay J, Siegel RL, et al., 2021, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3): 209–249. https://doi.org/10.3322/caac.21660

Hu W, Wang G, Huang D, et al., 2019, Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. Front Immunol, 10: 1205. https://doi.org/10.3389/fimmu.2019.01205

Wang W, Jiang J, Wu C, 2020, CAR-NK for Tumor Immunotherapy: Clinical Transformation and Future Prospects. Cancer Lett, 472: 175–180. https://doi.org/10.1016/j.canlet.2019.11.033

Xiao L, Cen D, Gan H, et al., 2019, Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients. Mol Ther, 27(6): 1114–1125. https://doi.org/10.1016/j.ymthe.2019.03.011